Biocompatibility describes how a medical device material interacts with living tissue and whether that interaction can produce local, systemic, or delayed adverse effects. In device development and regulatory translation, it appears in biological evaluation plans and reports, risk-management files, and technical documentation that support market authorization, where the scope of testing and the conclusions must be communicated clearly and consistently.
Biocompatibility appears in biological evaluation reports, risk-management files, IFUs, and technical documentation for EU and U.S. submissions. Translators must handle terms such as cytotoxicity, sensitization, irritation, and genotoxicity without introducing clinical claims or softening test limitations; terminology consistency across study reports, labels, and justification documents is critical for reviewers and notified bodies.
A frequent mistake is translating 'biocompatible' as an absolute guarantee of safety, when in fact testing only supports compatibility under defined conditions. Overstating biocompatibility may create a false safety claim in labeling or technical documentation, and reviewers may challenge the conclusion if the test scope is not accurately translated in the biological evaluation.
FDA, CE/MDR and NMPA reviewers assess the submitted wording itself. Regulatory bodies require traceable, accountable translation, and an inconsistent term can delay or fail a submission.
Angel Translation locks terms like this into a project terminology base before expert review begins, so the same source term resolves to the same target term across every document in a submission — and stays consistent in the next revision. See the 8-step AI + expert workflow.
Send us the files. Acknowledged in 4 hours, quoted in 24.
Request a Quote →Life Science solutions →